Clinical Audit of GI Endoscopic Complications in a Tertiary Care Hospital

NCT ID: NCT05228353

Last Updated: 2023-09-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

42471 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-01

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endoscopy of the upper gastrointestinal tract using fiberoptic endoscopes was introduced in the late 1950s and provided the first opportunity for direct visualization of the esophagus, stomach, and duodenum and colon in vivo. GI Endoscopy is usually considered a safe and effective procedure. However complications do exist and procedure related costs are significant. There is a lack of prospective studies on complications of diagnostic and therapeutic endoscopic procedures.There is a lack of prospective studies on complications of diagnostic and therapeutic endoscopic procedures. Knowledge of potential endoscopic adverse events, their expected frequency, and the risk factors for their occurrence may help to minimize the incidence of adverse events. Review of adverse events as part of a continuing quality improvement process may serve to educate endoscopists, help to reduce the risk of future adverse events, and improve the overall quality of endoscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1\. STUDY OBJECTIVES

1a. Primary objective - Clinical audit of complications in gastrointestinal endoscopy unit from a tertiary care centre.

1b. Secondary objective - NA

2\. STUDY POPULATION- Consecutive patients coming to the hospital for any gastrointestinal endoscopic procedure for 6 months duration and develops a complication.

3\. DESIGN AND DURATION OF THE STUDY- It will be an observational prospective audit of all consecutive patients coming to the hospital for any gastrointestinal endoscopic procedure for 6 months duration.

4\. METHODOLOGY

4a. SUBJECT RECRUITMENT - All patients who undergo any diagnostic or therapeutic endoscopic procedure during the period and develop any complication.

4b. RANDOMIZATION AND BLINDING- N/A

4c. STUDY METHODS- This observational study will be conducted after obtaining ethical clearance from institutional human ethical committee. All patients who undergo any endoscopic procedure during the period including upper gastrointestinal endoscopy, colonoscopy, endoscopic retrograde cholangiopancreatography (ERCP), Endoscopic Ultrasound (EUS), Peroral Endoscopic Myotomy (POEM), Enteroscopy, Endoscopic mucosal resection (EMR), Endoscopic Submucosal Resection (ESD), Submucosal Tunnel Endoscopic Resection (STER), Anti Reflux Mucosal resection (ARMS), Anti Reflux Mucosal ablation (ARMA), GERD-X, Endoscopic Sleeve Gastrectomy (ESG) and develops an complication will be enrolled in the study.

4d. STUDY PROCEDURE- For each patient who develops a complication , Following variables will be collected: Details of procedure, Indication of procedure, H/O Antiplatelets, anticoagulants, Any co-morbidity, Operator Characteristics, Time of procedure, Duration of procedure, Type of sedation, Time of detection of complication, Length of hospital stay/ICU stay, Mortality, Financial Cost, 30 days Follow-up, Re-admission rate, American Society of Anaesthesiologists (ASA) physical status classification, Relevant Images of the procedure, Relevant Videos of the procedure.

4e. METHODS OF ASSESSMENT- As per clinical protocol, each patient will be assessed by the primary investigator at 24 hours after their procedure to assess for possible symptoms and complications and to answer any questions. Further, for the purposes of this study, all patients will be contacted by telephone 30 days or more after their procedure. A standardized telephone interview and a review of the electronic medical record will be used to obtain follow-up data. Following complications will be recorded as per ASGE guidelines.

1. Perforation
2. Bleeding
3. Infection
4. Pancreatitis
5. Cardio-pulmonary adverse event
6. Pain/ discomfort
7. Gas explosion
8. Thromboembolism
9. Instrumental penetration/ impaction
10. Drug reaction
11. Mortality

4f.STOPPING OR DISCONTINUATION CRITERIA- N/A

5\. SAMPLE SIZE CALCULATION- Since this is a clinical audit, all the patients coming for GI endoscopic procedures and developing complications will be recorded.

6\. STATISTICAL ANALYSIS- Statistical analysis including both univariate and multivariate analysis, when appropriate, on available data. Univariate analysis will be conducted using chi-square test, Fisher's exact test, and relative risks with their 95% confidence intervals. Multivariate analysis of the main predictors of complications will be performed using a forward stepwise logistic regression model with the SAS statistical system. All candidate independent variables, age included, will be analyzed in a dichotomous manner.

7\. ETHICAL JUSTIFICATION OF THE STUDY- GI Endoscopy is a safe and effective procedure. However complications do exist and procedure related costs are significant. There is a lack of prospective studies on complications of diagnostic and therapeutic endoscopic procedures. This study aims to quantify and identify risk factors associated with endoscopy procedure complications. Knowledge of potential endoscopic adverse events, their expected frequency, and the risk factors for their occurrence may help to minimize the incidence of adverse events. Review of adverse events as part of a continuing quality improvement process may serve to educate endoscopists, help to reduce the risk of future adverse events, and improve the overall quality of endoscopy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endoscopy Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients who undergo any diagnostic or therapeutic endoscopic procedure during the period and develop any complication including:

* Diagnostic and therapeutic upper gastrointestinal endoscopy,
* Diagnostic and therapeutic colonoscopy,
* Endoscopic retrograde cholangiopancreatography (ERCP),
* Endoscopic Ultrasound (EUS),
* Peroral Endoscopic Myotomy (POEM),
* Enteroscopy (Antegrade, Retrograde or spiral)
* Endoscopic mucosal resection (EMR),
* Endoscopic Submucosal Resection (ESD),
* Submucosal Tunnel Endoscopic Resection (STER)
* Anti- Reflex Mucosal Ablation (ARMA)
* Anti- Reflex Mucosal Resection (ARMS)
* GERD-X
* Endoscopic Sleeve Gastrectomy (ESG)
* Intra-gastric Balloon insertion

Exclusion Criteria

* Those who are not willing to give the consent.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Asian Institute of Gastroenterology, India

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Inavolu Pradev, MBBS, MD, DM

Role: PRINCIPAL_INVESTIGATOR

Consultant

Hardik Rughwani, MBBS, MD, DM

Role: PRINCIPAL_INVESTIGATOR

Consultant

Mohan ramchandani, MBBS, MD, DM

Role: STUDY_DIRECTOR

Consultant

Nageshwar D Reddy, MBBS, MD, DM

Role: STUDY_CHAIR

Chief

Anudeep KV, MBBS, MD, DM

Role: PRINCIPAL_INVESTIGATOR

Consultant

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AIG Hospitals

Hyderabad, Telangana, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

References

Explore related publications, articles, or registry entries linked to this study.

Wolfsen HC, Hemminger LL, Achem SR, Loeb DS, Stark ME, Bouras EP, DeVault KR. Complications of endoscopy of the upper gastrointestinal tract: a single-center experience. Mayo Clin Proc. 2004 Oct;79(10):1264-7. doi: 10.4065/79.10.1264.

Reference Type RESULT
PMID: 15473407 (View on PubMed)

Mahnke D, Chen YK, Antillon MR, Brown WR, Mattison R, Shah RJ. A prospective study of complications of endoscopic retrograde cholangiopancreatography and endoscopic ultrasound in an ambulatory endoscopy center. Clin Gastroenterol Hepatol. 2006 Jul;4(7):924-30. doi: 10.1016/j.cgh.2006.04.006. Epub 2006 Jun 22.

Reference Type RESULT
PMID: 16797251 (View on PubMed)

Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, De Bernardin M, Ederle A, Fina P, Fratton A. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998 Jul;48(1):1-10. doi: 10.1016/s0016-5107(98)70121-x.

Reference Type RESULT
PMID: 9684657 (View on PubMed)

Levy I, Gralnek IM. Complications of diagnostic colonoscopy, upper endoscopy, and enteroscopy. Best Pract Res Clin Gastroenterol. 2016 Oct;30(5):705-718. doi: 10.1016/j.bpg.2016.09.005. Epub 2016 Sep 14.

Reference Type RESULT
PMID: 27931631 (View on PubMed)

Richter JM, Kelsey PB, Campbell EJ. Adverse Event and Complication Management in Gastrointestinal Endoscopy. Am J Gastroenterol. 2016 Mar;111(3):348-52. doi: 10.1038/ajg.2015.423. Epub 2016 Jan 12.

Reference Type RESULT
PMID: 26753887 (View on PubMed)

Dumonceau JM, Kapral C, Aabakken L, Papanikolaou IS, Tringali A, Vanbiervliet G, Beyna T, Dinis-Ribeiro M, Hritz I, Mariani A, Paspatis G, Radaelli F, Lakhtakia S, Veitch AM, van Hooft JE. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2020 Feb;52(2):127-149. doi: 10.1055/a-1075-4080. Epub 2019 Dec 20.

Reference Type RESULT
PMID: 31863440 (View on PubMed)

Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027. No abstract available.

Reference Type RESULT
PMID: 20189503 (View on PubMed)

Katrevula A, Singla N, Rughwani H, Jagtap N, Katukuri GR, Godbole S, Teles de Campos S, Memon SF, Inavolu P, Singh AP, Mathur SS, Ashraf A, Patel R, Haja A, Asif S, Katamareddy T, Kalapala R, Ramchandani M, Lakhtakia S, Santosh D, Reddy N. Comprehensive audit of gastrointestinal endoscopy adverse events: Emphasizing quality indicators and economic impact with the AIG-AGREE modification. Endosc Int Open. 2024 Oct 28;12(10):E1242-E1250. doi: 10.1055/a-2435-5445. eCollection 2024 Oct.

Reference Type DERIVED
PMID: 39474484 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AIG/IEC-BH&R 14/05.2021-03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Transnasal and Oral Gastroscopy.
NCT00273117 TERMINATED